119P - Efficacy and safety profile of eribulin mesylate in advanced breast cancer: Single-centre experience from India

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Breast Cancer, Metastatic
Presenter Ajay Sharma
Citation Annals of Oncology (2016) 27 (suppl_9): ix35-ix41. 10.1093/annonc/mdw577
Authors A. Sharma, D.C. Doval, K. Dutta, P. Goyal, R. Bajaj, M. Sharma, P. Jain
  • Medical Oncology, Rajiv Gandhi Cancer Institute, 110085 - Delhi/IN



Patients with advanced breast cancer are usually resistant to anthracyclines and taxanes. Treatment failure is observed in majority of metastatic breast cancer patients and 5 year survival rate is only 27%. Treatment guidelines do not recommend any single agent or a combination regimen in particular sequence for advanced breast cancer. Eribulin mesylate a microtubule polymerization inhibitor is the first single agent chemotherapy with proven overall survival benefit and tolerable safety profile in advanced breast cancer patients.


This is a retrospective analysis of 23 advanced breast cancer patients irrespective of hormone or HER2 receptor status. These patients were treated previously with anthracycline and/or taxanes and at least one chemotherapy for advanced disease. 1.4 mg/m2 eribulin mesylate was administered on day 1 and 8 of 21 days cycle until disease progression or occurrence of an unacceptable toxicity, or the patient not willing to continue the treatment.


Out of 23 patients analyzed, 11 patients responded to eribulin mesylate. Patients received average 4 cycles of eribulin mesylate. The objective response rate was 34.7% and clinical benefit rate was 47.8%. 8 patients had partial response. 4 patients even in 4th line of chemotherapy responded optimally to eribulin. Response rates were consistent in all patient subgroups. Neutropenia was the commonest reported adverse event (13%) followed by peripheral neuropathy (8.7%). Two patients reported grade 3 neutropenia and two patients reported grade 2/3 neuropathy. Disease progression was the most common reason for discontinuation of treatment with eribulin mesylate.


Our single centre experience shows clinical outcomes similar to phase III clinical trials of eribulin mesylate and real world data mentioned in literature.

Clinical trial indentification

Observational study

Legal entity responsible for the study

Rajiv Gandhi Cancer Institute




All authors have declared no conflicts of interest.